AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38849344 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone plus autologous stem cell transplantation
Number of subjects: 400
Study 38849604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modifications to increase protein intake
Number of subjects: 26
Study 38849605 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized PEEP strategy alongside extended lung protection
Number of subjects: 76
Study 38849605 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 76
Study 38849726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo tumor-derived models (PDTO, ADS, and explants)
Number of subjects: 0
Study 38849726 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy and PARP inhibitors
Number of subjects: 0
Study 38849734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen 800 mg
Number of subjects: 100
Study 38849734 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 100
Study 38849741 — intervention group
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-FAPI-46 PET/CT
Number of subjects: 50
Study 38849770 — intervention group
Group type: EXPERIMENTAL
Intervention: High nodal burden group
Number of subjects: 124
Study 38849770 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiP model based on PET-based radiomics
Number of subjects: 124
Study 38849782 — intervention group
Group type: EXPERIMENTAL
Intervention: Good School Toolkit-Primary intervention
Number of subjects: 1910
Study 38849829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily for 12 months
Number of subjects: 62
Study 38849829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 38849875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg capsule 1-2 hours before surgery
Number of subjects: 0
Study 38849875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38849905 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA-based assay
Number of subjects: 249
Study 38849943 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine (110 mg/m2)
Number of subjects: 411
Study 38849943 — intervention group
Group type: COMPARATOR
Intervention: Lomustine with reirradiation
Number of subjects: 411
Study 38849944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidomain lifestyle intervention after 20 weeks
Number of subjects: 51
Study 38849944 — intervention group
Group type: COMPARATOR
Intervention: Wait-list usual care control group
Number of subjects: 51
Study 38850034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 16
Study 38850034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 38850200 — intervention group
Group type: EXPERIMENTAL
Intervention: Excellent bowel cleansing (20,934 individuals)
Number of subjects: 35710
Study 38850200 — intervention group
Group type: EXPERIMENTAL
Intervention: Good bowel cleansing (6,580 individuals)
Number of subjects: 35710
Study 38850200 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly poor bowel cleansing (7,097 individuals)
Number of subjects: 35710
Study 38850200 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor bowel cleansing (1,099 individuals)
Number of subjects: 35710
Study 38850311 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-68-labeled FAP inhibitor 04
Number of subjects: 0
Study 38850311 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38850317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 235
Study 38850402 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive cenobamate
Number of subjects: 40
Study 38850466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-kg load
Number of subjects: 75
Study 38850466 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-kg load
Number of subjects: 75
Study 38850466 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-kg load
Number of subjects: 75
Study 38850466 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld weights
Number of subjects: 75
Study 38850466 — intervention group
Group type: COMPARATOR
Intervention: Rotator cuff tears
Number of subjects: 75
Study 38850687 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical adjudication process for evaluating infection status
Number of subjects: 955
Study 38850996 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate ORS
Number of subjects: 14
Study 38851019 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative videos and mini-VR games
Number of subjects: 26
Study 38851019 — intervention group
Group type: COMPARATOR
Intervention: Control group (tutorial including case-based discussions and role-play)
Number of subjects: 26
Study 38851039 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLSTER
Number of subjects: 77
Study 38851039 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Discharge Planning (EDP)
Number of subjects: 77
Study 38851166 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8189 12 mg
Number of subjects: 224
Study 38851166 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg (active control)
Number of subjects: 224
Study 38851166 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8189
Number of subjects: 224
Study 38851203 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment (specific intervention details not provided)
Number of subjects: 226
Study 38851203 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 226
Study 38851207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (10 mg/kg intravenously) and Pembrolizumab (200 mg intravenously)
Number of subjects: 40
Study 38851225 — intervention group
Group type: EXPERIMENTAL
Intervention: Malkia Klabu (Queen Club) intervention at ADDOs providing free contraceptives and oral HIV self-test kits, with a customer loyalty programme.
Number of subjects: 120
Study 38851225 — intervention group
Group type: EXPERIMENTAL
Intervention: Malkia Klabu intervention
Number of subjects: 120
Study 38851226 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 99
Study 38851232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivomixx (450 billion colony-forming units per sachet) taken once daily until 1 week postpartum
Number of subjects: 94
Study 38851232 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken once daily until 1 week postpartum
Number of subjects: 94
Study 38851232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivomixx
Number of subjects: 94
Study 38851232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 38851233 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring and oral glucose tolerance testing
Number of subjects: 2150
Study 38851400 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness assessment through questionnaires
Number of subjects: 2000
Study 38851457 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 50
Study 38851457 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 38851462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg IV once daily for 7-14 days
Number of subjects: 525
Study 38851462 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin IV once daily for 7-14 days
Number of subjects: 525
Study 38851462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Number of subjects: 525
Study 38851462 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 525
Study 38851554 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching (OPC)
Number of subjects: 30
Study 38851554 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 30
Study 38851555 — intervention group
Group type: COMPARATOR
Intervention: Button hole technique (BG)
Number of subjects: 108
Study 38851555 — intervention group
Group type: COMPARATOR
Intervention: I-band technique (IG)
Number of subjects: 108
Study 38851555 — intervention group
Group type: COMPARATOR
Intervention: Exercises (EG)
Number of subjects: 108
Study 38851634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-protein, and high-fiber (LFHP) diet
Number of subjects: 0
Study 38851634 — intervention group
Group type: COMPARATOR
Intervention: High-monounsaturated fatty acid (HMUFA) diet
Number of subjects: 0
Study 38851666 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of benzodiazepines for insomnia, delirium, and agitation in the elderly
Number of subjects: 33
Study 38851666 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of hypnotics without a previous etiological diagnosis
Number of subjects: 33
Study 38851676 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional heat-cured acrylic resin overdenture
Number of subjects: 16
Study 38851676 — intervention group
Group type: COMPARATOR
Intervention: 3D-printed mandibular implant overdenture
Number of subjects: 16
Study 38851706 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels among PLWH
Number of subjects: 300
Study 38851706 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle index among PLWH
Number of subjects: 300
Study 38851706 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength among PLWH
Number of subjects: 300
Study 38851706 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT) performance among PLWH
Number of subjects: 300
Study 38851706 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity level among PLWH
Number of subjects: 300
Study 38851706 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity limitations among PLWH
Number of subjects: 300
Study 38851706 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression levels among PLWH
Number of subjects: 300
Study 38851706 — intervention group
Group type: EXPERIMENTAL
Intervention: Social functioning scores among PLWH
Number of subjects: 300
Study 38851710 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy plus drug-coated balloon (DCB)
Number of subjects: 306
Study 38851710 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 306
Study 38851719 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Skills Together (LST) intervention
Number of subjects: 200
Study 38851719 — intervention group
Group type: COMPARATOR
Intervention: Control condition focused on healthy living
Number of subjects: 200
Study 38851732 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-session, group-based behavioral intervention delivered via videoconferencing.
Number of subjects: 61
Study 38851732 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group.
Number of subjects: 61
Study 38852061 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind/Body Program for Infertility (MBPI)
Number of subjects: 168
Study 38852061 — intervention group
Group type: COMPARATOR
Intervention: Fertility Support (FS)
Number of subjects: 168
Study 38852114 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral FTC/TDF
Number of subjects: 247
Study 38852114 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine ring
Number of subjects: 247
Study 38852330 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT + FFDM
Number of subjects: 48
Study 38852330 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT + S2D
Number of subjects: 48
Study 38852330 — intervention group
Group type: COMPARATOR
Intervention: FFDM
Number of subjects: 48
Study 38852330 — intervention group
Group type: COMPARATOR
Intervention: Radiologists
Number of subjects: 48
Study 38852330 — intervention group
Group type: COMPARATOR
Intervention: Radiographers
Number of subjects: 48
Study 38852330 — intervention group
Group type: EXPERIMENTAL
Intervention: Readers with 5+ years DBT experience
Number of subjects: 48
Study 38852330 — intervention group
Group type: EXPERIMENTAL
Intervention: Readers with less than 9 months DBT experience
Number of subjects: 48
Study 38852379 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with endocrine therapy (letrozole or fulvestrant)
Number of subjects: 90
Study 38852379 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 90
Study 38852601 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant camrelizumab (200 mg IV on day 1) plus apatinib (250 mg orally from day 1-14, every 3 weeks for 3 months)
Number of subjects: 53
Study 38852601 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant camrelizumab plus apatinib
Number of subjects: 53
Study 38852600 — intervention group
Group type: EXPERIMENTAL
Intervention: Burr-hole drainage with subdural irrigation
Number of subjects: 589
Study 38852600 — intervention group
Group type: COMPARATOR
Intervention: Burr-hole drainage without subdural irrigation
Number of subjects: 589
Study 38852675 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront primary tumor resection (PTR) followed by systemic therapy
Number of subjects: 204
Study 38852675 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy without upfront PTR
Number of subjects: 204
Study 38852760 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate treatment for three months
Number of subjects: 442
Study 38852770 — intervention group
Group type: EXPERIMENTAL
Intervention: ASMD trial patients (before exposure to treatment)
Number of subjects: 18
Study 38852770 — intervention group
Group type: COMPARATOR
Intervention: ASMD non-trial participants
Number of subjects: 18
Study 38852906 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages sent to caregivers advising how to reschedule the missed appointment.
Number of subjects: 720
Study 38852906 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control group).
Number of subjects: 720
Study 38852934 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0
Study 38852934 — intervention group
Group type: COMPARATOR
Intervention: PDE5i
Number of subjects: 0
Study 38853036 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF
Number of subjects: 230
Study 38853244 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy signature using circulating biomarkers
Number of subjects: 355
Study 38853244 — intervention group
Group type: COMPARATOR
Intervention: Validation of multi-marker panel
Number of subjects: 355
Study 38853244 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of a liquid biopsy biobank
Number of subjects: 355
Study 38853251 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management (GAM) intervention
Number of subjects: 178
Study 38853251 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control)
Number of subjects: 178
Study 38853265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with chemotherapy (albumin-bound paclitaxel and carboplatin) for up to four cycles
Number of subjects: 35
Study 38853265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with chemotherapy
Number of subjects: 35
Study 38853269 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-ingredient pre-workout dietary supplement (MIPS)
Number of subjects: 12
Study 38853269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 38853394 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg twice daily and Amoxicillin 750 mg four times daily (TA group)
Number of subjects: 368
Study 38853394 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg and Amoxicillin 750 mg four times daily (EA group)
Number of subjects: 368
Study 38853420 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood ketone meter use (Intervention)
Number of subjects: 388
Study 38853420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital fluid therapy (Intervention)
Number of subjects: 388
Study 38853420 — intervention group
Group type: COMPARATOR
Intervention: Pre-hospital fluid therapy (Control)
Number of subjects: 388
Study 38853420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulance capillary blood ketone meter use (Intervention)
Number of subjects: 388
Study 38853438 — intervention group
Group type: EXPERIMENTAL
Intervention: MYTX-011
Number of subjects: 0
Study 38853607 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 589
Study 38853607 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir
Number of subjects: 589
Study 38853614 — intervention group
Group type: EXPERIMENTAL
Intervention: altSonflex1-2-3
Number of subjects: 102
Study 38853614 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 102
Study 38853689 — intervention group
Group type: EXPERIMENTAL
Intervention: oHSV therapy (rQNestin34.5v.2)
Number of subjects: 14
Study 38853689 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion of IGF2
Number of subjects: 14
Study 38853689 — intervention group
Group type: EXPERIMENTAL
Intervention: oHSV-D11mt (modified IGF2R domain 11)
Number of subjects: 14
Study 38853879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds (CMBs)
Number of subjects: 1352
Study 38853879 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter hyperintensities (WMH)
Number of subjects: 1352
Study 38853879 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diagnostic model including CVD biomarkers
Number of subjects: 1352
Study 38853894 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in non-farming occupations for women
Number of subjects: 31867
Study 38853894 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 31867
Study 38853894 — intervention group
Group type: EXPERIMENTAL
Intervention: Wealth quintile
Number of subjects: 31867
Study 38853894 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-short stature (nutritional status)
Number of subjects: 31867
Study 38853894 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate interpregnancy interval (obstetric history)
Number of subjects: 31867
Study 38853894 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior pregnancy but no live birth (obstetric history)
Number of subjects: 31867
Study 38853894 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of vaginal bleeding
Number of subjects: 31867
Study 38853894 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of the government's conditional cash transfer ANC program
Number of subjects: 31867
Study 38853894 — intervention group
Group type: COMPARATOR
Intervention: Belonging to the lower Shudra caste
Number of subjects: 31867
Study 38853894 — intervention group
Group type: COMPARATOR
Intervention: Maternal age below 18 or above 35
Number of subjects: 31867
Study 38853894 — intervention group
Group type: COMPARATOR
Intervention: Preterm birth
Number of subjects: 31867
Study 38853894 — intervention group
Group type: COMPARATOR
Intervention: Parity ≥ 1
Number of subjects: 31867
Study 38853894 — intervention group
Group type: COMPARATOR
Intervention: Presence of hypertension during pregnancy
Number of subjects: 31867
Study 38853958 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Bright Light Therapy (MBLT); n=80; 60-min duration; daily over 28-day duration.
Number of subjects: 120
Study 38853958 — intervention group
Group type: COMPARATOR
Intervention: Sham: deactivated negative ion generator; n=40; 60-min duration; daily over 28-day duration.
Number of subjects: 120
Study 38854081 — intervention group
Group type: EXPERIMENTAL
Intervention: LAFIYA intervention
Number of subjects: 240
Study 38854081 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 240
Study 38854091 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (100 mg every 12h)
Number of subjects: 16
Study 38854091 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (250 mg every 12h)
Number of subjects: 16
Study 38854091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 38854392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensovibep (75, 225, or 600 mg)
Number of subjects: 407
Study 38854392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 38854417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily (BID)
Number of subjects: 4967
Study 38854418 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise (30 minutes, five times per week for 12 weeks)
Number of subjects: 20
Study 38854418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study 38854653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (high-risk strategy for prevention of cardiovascular diseases)
Number of subjects: 5654
Study 38854653 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 5654
Study 38854740 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 52 weeks
Number of subjects: 303
Study 38854740 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks for 52 weeks
Number of subjects: 303
Study 38854853 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM 2.0 software
Number of subjects: 245
Study 38854853 — intervention group
Group type: COMPARATOR
Intervention: Standard Tablet (Control)
Number of subjects: 245
Study 38854963 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal balloon angioplasty (SBA) combined with standard medical therapy
Number of subjects: 416
Study 38854963 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 416
Study 38855456 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFPAS mobile application
Number of subjects: 20
Study 38855456 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 20
Study 38855639 — intervention group
Group type: EXPERIMENTAL
Intervention: IFIP intervention including implementation interventions and clinical interventions (BFIS and FPE)
Number of subjects: 231
Study 38855639 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 231
Study 38855639 — intervention group
Group type: EXPERIMENTAL
Intervention: IFIP intervention
Number of subjects: 231
Study 38855751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Atorvastatin (80 mg) once daily
Number of subjects: 60
Study 38855751 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine + Placebo once daily
Number of subjects: 60